This provides evidence that high expression of CXCL9 and CXCL10 in the intra-tumor environment of the body is significantly correlated with a high density of CD8+ T cells and that increased selective expression of CXCL9 and CXCL10 in Treg cell-depleted tumors may serve as a potential immunotherapy. Here, CXCL10 is linked to neoplasm.